Trials / Completed
CompletedNCT00717015
Tamoxifen Pharmacokinetics and CYP2D6 Polymorphisms in Asian Women With Hormone Receptor Positive Breast Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- —
- Sponsor
- National University Hospital, Singapore · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
We hypothesized that subjects with CYP2D6\*10 alleles may have a lower steady state levels of endoxifen due to reduced conversion of tamoxifen to endoxifen. Primary objectives: * To determine the steady state pharmacokinetics of tamoxifen and its metabolites * To test the effects of genetic polymorphisms of CYP2D6 on plasma concentration of tamoxifen and its metabolites in hormone receptor positive women who are taking tamoxifen as adjuvant treatment for breast cancer.
Conditions
Timeline
- Start date
- 2005-11-01
- First posted
- 2008-07-16
- Last updated
- 2012-04-03
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT00717015. Inclusion in this directory is not an endorsement.